Yelena Chistyakova, MD
Psychiatry · Decatur, ALNPI 1295944056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 506 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,937, 3.2 times the $598 reported in 2019. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$985
- Teva Pharmaceuticals USA, Inc.$799
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$680
- Takeda Pharmaceuticals U.S.A., Inc.$659
- plus $4K from 20 others
What the payments were for
- Food & beverage$9,196100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 65 | $1,290 |
| AbbVie(2 entities) | 59 | $1,133 |
| Otsuka America Pharmaceutical, Inc. | 53 | $985 |
| Teva Pharmaceuticals USA, Inc. | 46 | $799 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $680 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $659 |
| Sunovion Pharmaceuticals Inc. | 49 | $642 |
| Lundbeck LLC | 19 | $444 |
| Corium, LLC | 27 | $419 |
| Neurocrine Biosciences, Inc. | 21 | $402 |
| Vanda Pharmaceuticals Inc. | 16 | $336 |
| Johnson & Johnson | 18 | $321 |
| Almatica Pharma LLC | 14 | $297 |
| Axsome Therapeutics, Inc. | 11 | $180 |
| Bausch Health US, LLC | 8 | $153 |
| Avanir Pharmaceuticals, Inc. | 6 | $118 |
| Merck | 6 | $101 |
| Idorsia Pharmaceuticals US Inc | 3 | $42 |
| Eisai Inc. | 3 | $39 |
| Adlon Therapeutics L.p. | 3 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Indivior Inc. | 1 | $19 |
| Neos Therapeutics, LP | 1 | $18 |
| Tris Pharma Inc | 1 | $17 |
| Bioxcel Therapeutics, Inc. | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
How this compares
$9,196 in reported general payments places this provider in the 90th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 16 | $206,134 |
| VraylarCariprazine Hcl | 117 | $174,446 |
| Invega SustennaPaliperidone Palmitate | 26 | $93,407 |
| TrintellixVortioxetine Hydrobromide | 82 | $39,583 |
| BelsomraSuvorexant | 55 | $23,604 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $19,784 |
| Lurasidone Hcl | 110 | $17,333 |
| SavellaMilnacipran Hcl | 30 | $14,746 |
| Ziprasidone Hcl | 180 | $10,162 |
| Quetiapine Fumarate | 432 | $8,955 |
| Duloxetine Hcl | 259 | $7,474 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 278 | $7,389 |
| Gabapentin | 472 | $6,512 |
| Aripiprazole | 204 | $5,596 |
| Prazosin Hcl | 308 | $5,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $799 | $206,13416 claims |
| AbbVieVraylar, Savella | $1,133 | $189,193147 claims |
| Johnson & JohnsonInvega Sustenna | $321 | $93,40726 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $659 | $39,58382 claims |
| MerckBelsomra | $101 | $23,60455 claims |
| Alkermes, Inc.Lybalvi | $1,290 | $19,78413 claims |
| Almatica Pharma LLCSertraline Hcl | $297 | $1,618180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Decatur
- Albert SprinkleDecatur$4K
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Scariya KumaramangalamHuntsville$440K
- Mark HaygoodMobile$348K
- Lori DavisTuscaloosa$161K
- Bradley SadlerMobile$124K
- Brandi Rudolph BollingJasper$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.